Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

Nature Medicine

Volumn 14, Issue 5, 2008, Pages 579-584

  Li, Jin ^a   Wang, Lilin ^a   Mamon, Harvey ^a   Kulke, Matthew H ^a   Berbeco, Ross ^a   Makrigiorgos, G Mike ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; PROTEIN P53;

ALLELE; ARTICLE; CANCER DIAGNOSIS; CO AMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENOTYPE; HUMAN; HUMAN CELL; MATERNAL BLOOD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WILD TYPE;

CELL LINE, TUMOR; COLD; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43249116705     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1708     Document Type: Article

References (27)

1. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
2. Hoffmann, C. et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 35, e91 (2007).
3. Lo, Y.M. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485-487 (1997).
4. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
5. Janne, P.A. et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin. Cancer Res. 12, 751-758 (2006).
6. Engelman, J.A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695-2706 (2006).
7. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102, 16368-16373 (2005).
8. Kimura, T. et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann. NY Acad. Sci. 1022, 55-60 (2004).
9. Li, J. et al. s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. Nucleic Acids Res. 35, e84 (2007).
10. Lipsky, R.H. et al. DNA melting analysis for detection of single nucleotide polymorphisms. Clin. Chem. 47, 635-644 (2001).
11. Liew, M. et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin. Chem. 50, 1156-1164 (2004).
12. Yeung, A.T., Hattangadi, D., Blakesley, L. & Nicolas, E. Enzymatic mutation detection technologies. Biotechniques 38, 749-758 (2005).
13. Ogino, S. et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J. Mol. Diagn. 7, 413-421 (2005).
14. Huang, C. et al. Mutations in exon 7 and 8 of TP53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16, 2469-2477 (1998).
15. Huang, C.L. et al. Mutations of TP53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int. J. Oncol. 12, 553-563 (1998).
16. Jackson, P.E. et al. Specific TP53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 61, 33-35 (2001).
17. Shao, Z.M., Wu, J., Shen, Z.Z. & Nguyen, M. TP53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin. Cancer Res. 7, 2222-2227 (2001).
18. Mayall, F., Jacobson, G., Wilkins, R. & Chang, B. Mutations of TP53 gene can be detected in the plasma of patients with large bowel carcinoma. J. Clin. Pathol. 51, 611-613 (1998).
19. Silva, J.M. et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8, 3761-3766 (2002).
20. Gonzalez, R. et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann. Oncol. 11, 1097-1104 (2000).
21. Eberhard, D.A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
22. Thomas, R.K. et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat. Med. 12, 852-855 (2006).
23. Thomas, R.K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
24. Sun, X., Hung, K., Wu, L., Sidransky, D. & Guo, B. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nat. Biotechnol. 20, 186-189 (2002).
25. Fuery, C.J. et al. Detection of rare mutant alleles by restriction endonuclease-mediated selective-PCR: assay design and optimization. Clin. Chem. 46, 620-624 (2000).
26. Belinsky, S.A. et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 11, 6505-6511 (2005).
27. Greenman, C. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).